Table of Contents
ISRN Cardiology
Volume 2011 (2011), Article ID 397136, 16 pages
http://dx.doi.org/10.5402/2011/397136
Review Article

Effects of Some Common Food Constituents on Cardiovascular Disease

1Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
2Centre for Clinical Pharmacology, University College London, London WC1E 6JF, UK

Received 14 March 2011; Accepted 19 April 2011

Academic Editors: C. Briguori, E. Z. Fisman, A. Ganau, and A. M. Gerdes

Copyright © 2011 Yaling Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Yusuf, S. Hawken, S. Ôunpuu et al., “Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study,” Lancet, vol. 364, no. 9438, pp. 937–952, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. S. T. Chen, N. M. Maruthur, and L. J. Appel, “The effect of dietary patterns on estimated coronary heart disease risk results from the dietary approaches to stop hypertension trial,” Circulation: Cardiovascular Quality and Outcomes, vol. 3, no. 5, pp. 484–489, 2010. View at Publisher · View at Google Scholar · View at PubMed
  3. “State-specific trends in fruit and vegetable consumption among adults—United States, 2000–2009,” Morbidity and Mortality Weekly Report, vol. 59, no. 35, pp. 1125–1130, 2010.
  4. P. Di Mascio, S. Kaiser, and H. Sies, “Lycopene as the most efficient biological carotenoid singlet oxygen quencher,” Archives of Biochemistry and Biophysics, vol. 274, no. 2, pp. 532–538, 1989. View at Google Scholar · View at Scopus
  5. A. Bub, B. Watzl, L. Abrahamse et al., “Moderate intervention with carotenoid-rich vegetable products reduces lipid peroxidation in men,” Journal of Nutrition, vol. 130, no. 9, pp. 2200–2206, 2000. View at Google Scholar · View at Scopus
  6. S. Agarwal and A. V. Rao, “Tomato lycopene and low density lipoprotein oxidation: a human dietary intervention study,” Lipids, vol. 33, no. 10, pp. 981–984, 1998. View at Google Scholar · View at Scopus
  7. E. R. Greenberg, J. A. Baron, M. R. Karagas et al., “Mortality associated with low plasma concentration of beta carotene and the effect of oral supplementation,” Journal of the American Medical Association, vol. 275, no. 9, pp. 699–703, 1996. View at Publisher · View at Google Scholar · View at Scopus
  8. K. F. Gey and P. Puska, “Plasma vitamins E and A inversely correlated to mortality from ischemic heart disease in cross-cultural epidemiology,” Annals of the New York Academy of Sciences, vol. 570, pp. 268–282, 1989. View at Google Scholar · View at Scopus
  9. A. F. M. Kardinaal, F. J. Kok, J. Ringstad et al., “Antioxidants in adipose tissue and risk of myocardial infarction: the EURAMIC study,” Lancet, vol. 342, no. 8884, pp. 1379–1384, 1993. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Tavani, E. Negri, B. D'Avanzo, and C. La Vecchia, “Beta-carotene intake and risk of nonfatal acute myocardial infarction in women,” European Journal of Epidemiology, vol. 13, no. 6, pp. 631–637, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Klipstein-Grobusch, J. M. Geleijnse, J. H. den Breeijen et al., “Dietary antioxidants and risk of myocardial infarction in the elderly: the Rotterdam study,” American Journal of Clinical Nutrition, vol. 69, no. 2, pp. 261–266, 1999. View at Google Scholar · View at Scopus
  12. E. B. Rimm, M. J. Stampfer, A. Ascherio, E. Giovannucci, G. A. Colditz, and W. C. Willett, “Vitamin E consumption and the risk of coronary heart disease in men,” New England Journal of Medicine, vol. 328, no. 20, pp. 1450–1456, 1993. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  13. Heart Protection Study Collaborative Group, “MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial,” Lancet, vol. 360, no. 9326, pp. 23–33, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. J. M. Rapola, J. Virtamo, S. Ripatti et al., “Randomised trial of α-tocopherol and β-carotene supplements on incidence of major coronary events in men with previous myocardial infarction,” Lancet, vol. 349, no. 9067, pp. 1715–1720, 1997. View at Publisher · View at Google Scholar · View at Scopus
  15. N. R. Cook, C. M. Albert, J. M. Gaziano et al., “A randomized factorial trial of vitamins C and E and beta carotene in the secondary prevention of cardiovascular events in women: results from the women's antioxidant cardiovascular study,” Archives of Internal Medicine, vol. 167, no. 15, pp. 1610–1618, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. S. Liu, I. M. Lee, U. Ajani, S. R. Cole, J. E. Buring, and J. E. Manson, “Intake of vegetables rich in carotenoids and risk of coronary heart disease in men: the physicians' health study,” International Journal of Epidemiology, vol. 30, no. 1, pp. 130–135, 2001. View at Google Scholar · View at Scopus
  17. C. H. Hennekens, J. E. Buring, J. E. Manson et al., “Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease,” New England Journal of Medicine, vol. 334, no. 18, pp. 1145–1149, 1996. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. N. J. Miller, J. Sampson, L. P. Candeias, P. M. Bramley, and C. A. Rice-Evans, “Antioxidant activities of carotenes and xanthophylls,” FEBS Letters, vol. 384, no. 3, pp. 240–242, 1996. View at Publisher · View at Google Scholar · View at Scopus
  19. A. V. Rao and S. Agarwal, “Role of antioxidant lycopene in cancer and heart disease,” Journal of the American College of Nutrition, vol. 19, no. 5, pp. 563–569, 2000. View at Google Scholar · View at Scopus
  20. L. Kohlmeier, J. D. Kark, E. Gomez-Gracia et al., “Lycopene and myocardial infarction risk in the EURAMIC study,” American Journal of Epidemiology, vol. 146, no. 8, pp. 618–626, 1997. View at Google Scholar · View at Scopus
  21. T. H. Rissanen, S. Voutilainen, K. Nyyssönen, R. Salonen, G. A. Kaplan, and J. T. Salonen, “Serum lycopene concentrations and carotid atherosclerosis: the Kuopio Ischaemic Heart Disease Risk Factor Study,” American Journal of Clinical Nutrition, vol. 77, no. 1, pp. 133–138, 2003. View at Google Scholar · View at Scopus
  22. H. D. Sesso, J. E. Buring, E. P. Norkus, and J. M. Gaziano, “Plasma lycopene, other carotenoids, and retinol and the risk of cardiovascular disease in men,” American Journal of Clinical Nutrition, vol. 81, no. 5, pp. 990–997, 2005. View at Google Scholar · View at Scopus
  23. G. Riccioni, B. Mancini, E. Di Ilio, T. Bucciarelli, and N. D'Orazio, “Protective effect of lycopene in cardiovascular disease,” European Review for Medical and Pharmacological Sciences, vol. 12, no. 3, pp. 183–190, 2008. View at Google Scholar · View at Scopus
  24. S. Blankenberg, H. J. Rupprecht, C. Bickel et al., “Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease,” New England Journal of Medicine, vol. 349, no. 17, pp. 1605–1613, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. H. Shimizu, Y. Kiyohara, I. Kato et al., “Relationship between plasma glutathione levels and cardiovascular disease in a defined population: the Hisayama study,” Stroke, vol. 35, no. 9, pp. 2072–2077, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. N. K. Hollenberg, N. D. Fisher, and M. L. McCullough, “Flavanols, the Kuna, cocoa consumption, and nitric oxide,” Journal of the American Society of Hypertension, vol. 3, no. 2, pp. 105–112, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. J. F. Hammerstone, S. A. Lazarus, A. E. Mitchell, R. Rucker, and H. H. Schmitz, “Identification of procyanidins in cocoa (Theobroma cacao) and chocolate using high-performance liquid chromatography/mass spectrometry,” Journal of Agricultural and Food Chemistry, vol. 47, no. 2, pp. 490–496, 1999. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Manach, A. Scalbert, C. Morand, C. Rémésy, and L. Jiménez, “Polyphenols: food sources and bioavailability,” American Journal of Clinical Nutrition, vol. 79, no. 5, pp. 727–747, 2004. View at Google Scholar · View at Scopus
  29. B. Buijsse, C. Weikert, D. Drogan, M. Bergmann, and H. Boeing, “Chocolate consumption in relation to blood pressure and risk of cardiovascular disease in German adults,” European Heart Journal, vol. 31, no. 13, pp. 1616–1623, 2010. View at Publisher · View at Google Scholar · View at PubMed
  30. I. Janszky, K. J. Mukamal, R. Ljung, S. Ahnve, A. Ahlbom, and J. Hallqvist, “Chocolate consumption and mortality following a first acute myocardial infarction: the Stockholm Heart Epidemiology Program,” Journal of Internal Medicine, vol. 266, no. 3, pp. 248–257, 2009. View at Publisher · View at Google Scholar
  31. E. Mostofsky, E. B. Levitan, A. Wolk, and M. A. Mittleman, “Chocolate intake and incidence of heart failure a population-based prospective study of middle-aged and elderly women,” Circulation: Heart Failure, vol. 3, no. 5, pp. 612–616, 2010. View at Publisher · View at Google Scholar · View at PubMed
  32. S. Kuriyama, T. Shimazu, K. Ohmori et al., “Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study,” Journal of the American Medical Association, vol. 296, no. 10, pp. 1255–1265, 2006. View at Publisher · View at Google Scholar · View at PubMed
  33. K. Nakachi, S. Matsuyama, S. Miyake, M. Suganuma, and K. Imai, “Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention,” BioFactors, vol. 13, no. 1–4, pp. 49–54, 2000. View at Google Scholar
  34. N. Tanabe, H. Suzuki, Y. Aizawa, and N. Seki, “Consumption of green and roasted teas and the risk of stroke incidence: results from the Tokamachi-Nakasato cohort study in Japan,” International Journal of Epidemiology, vol. 37, no. 5, pp. 1030–1040, 2008. View at Publisher · View at Google Scholar · View at PubMed
  35. Y. C. Yang, F. H. Lu, J. S. Wu, C. H. Wu, and C. J. Chang, “The protective effect of habitual tea consumption on hypertension,” Archives of Internal Medicine, vol. 164, no. 14, pp. 1534–1540, 2004. View at Publisher · View at Google Scholar · View at PubMed
  36. M. Gronbaek, A. Deis, T. I. A. Sorensen, U. Becker, P. Schnohr, and G. Jensen, “Mortality associated with moderate intakes of wine, beer, or spirits,” British Medical Journal, vol. 310, no. 6988, pp. 1165–1169, 1995. View at Google Scholar
  37. R. di Giuseppe, A. Di Castelnuovo, F. Centritto et al., “Regular consumption of dark chocolate is associated with low serum concentrations of C-reactive protein in a healthy italian population,” Journal of Nutrition, vol. 138, no. 10, pp. 1939–1945, 2008. View at Google Scholar
  38. Y. Steffen, T. Schewe, and H. Sies, “(-)-Epicatechin elevates nitric oxide in endothelial cells via inhibition of NADPH oxidase,” Biochemical and Biophysical Research Communications, vol. 359, no. 3, pp. 828–833, 2007. View at Publisher · View at Google Scholar · View at PubMed
  39. M. Karim, K. McCormick, and C. T. Kappagoda, “Effects of cocoa extracts on endothelium-dependent relaxation,” Journal of Nutrition, vol. 130, no. 8, pp. 2105S–2108S, 2000. View at Google Scholar
  40. O. Schnorr, T. Brossette, T. Y. Momma et al., “Cocoa flavanols lower vascular arginase activity in human endothelial cells in vitro and in erythrocytes in vivo,” Archives of Biochemistry and Biophysics, vol. 476, no. 2, pp. 211–215, 2008. View at Publisher · View at Google Scholar · View at PubMed
  41. M. A. Creager, S. J. Gallagher, X. J. Girerd, S. M. Coleman, V. J. Dzau, and J. P. Cooke, “L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans,” Journal of Clinical Investigation, vol. 90, no. 4, pp. 1248–1253, 1992. View at Google Scholar
  42. M. R. Adams, R. McCredie, W. Jessup, J. Robinson, D. Sullivan, and D. S. Celermajer, “Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease,” Atherosclerosis, vol. 129, no. 2, pp. 261–269, 1997. View at Publisher · View at Google Scholar
  43. C. Heiss, D. Finis, P. Kleinbongard et al., “Sustained increase in flow-mediated dilation after daily intake of high-flavanol cocoa drink over 1 week,” Journal of Cardiovascular Pharmacology, vol. 49, no. 2, pp. 74–80, 2007. View at Publisher · View at Google Scholar · View at PubMed
  44. A. J. Flammer, F. Hermann, I. Sudano et al., “Dark chocolate improves coronary vasomotion and reduces platelet reactivity,” Circulation, vol. 116, no. 21, pp. 2376–2382, 2007. View at Publisher · View at Google Scholar · View at PubMed
  45. S. Desch, J. Schmidt, D. Kobler et al., “Effect of cocoa products on blood pressure: systematic review and meta-analysis,” American Journal of Hypertension, vol. 23, no. 1, pp. 97–103, 2010. View at Publisher · View at Google Scholar · View at PubMed
  46. L. Hooper, P. A. Kroon, E. B. Rimm et al., “Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials,” American Journal of Clinical Nutrition, vol. 88, no. 1, pp. 38–50, 2008. View at Google Scholar
  47. R. R. Holt, D. D. Schramm, C. L. Keen, S. A. Lazarus, and H. H. Schmitz, “Chocolate consumption and platelet function,” Journal of the American Medical Association, vol. 287, no. 17, pp. 2212–2213, 2002. View at Google Scholar
  48. D. A. Pearson, T. G. Paglieroni, D. Rein et al., “The effects of flavanol-rich cocoa and aspirin on ex vivo platelet function,” Thrombosis Research, vol. 106, no. 4-5, pp. 191–197, 2002. View at Publisher · View at Google Scholar
  49. R. Mehrinfar and W. H. Frishman, “Flavanol-rich cocoa: a cardioprotective nutraceutical,” Cardiology in Review, vol. 16, no. 3, pp. 109–115, 2008. View at Publisher · View at Google Scholar · View at PubMed
  50. J. B. Paquay, G. R. Haenen, G. Stender, S. A. Wiseman, L. B. Tijburg, and A. Bast, “Protection against nitric oxide toxicity by tea,” Journal of Agricultural and Food Chemistry, vol. 48, no. 11, pp. 5768–5772, 2000. View at Publisher · View at Google Scholar
  51. Y. L. Lin and J. K. Lin, “(-)-epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-κB,” Molecular Pharmacology, vol. 52, no. 3, pp. 465–472, 1997. View at Google Scholar
  52. K. Takano, K. Nakaima, M. Nitta, F. Shibata, and H. Nakagawa, “Inhibitory effect of (-)-epigallocatechin 3-gallate, a polyphenol of green tea, on neutrophil chemotaxis in vitro and in vivo,” Journal of Agricultural and Food Chemistry, vol. 52, no. 14, pp. 4571–4576, 2004. View at Publisher · View at Google Scholar · View at PubMed
  53. A. Ludwig, M. Lorenz, N. Grimbo et al., “The tea flavonoid epigallocatechin-3-gallate reduces cytokine-induced VCAM-1 expression and monocyte adhesion to endothelial cells,” Biochemical and Biophysical Research Communications, vol. 316, no. 3, pp. 659–665, 2004. View at Publisher · View at Google Scholar · View at PubMed
  54. K. Kawai, N. H. Tsuno, J. Kitayama et al., “Epigallocatechin gallate induces apoptosis of monocytes,” Journal of Allergy and Clinical Immunology, vol. 115, no. 1, pp. 186–191, 2005. View at Publisher · View at Google Scholar · View at PubMed
  55. S. I. Koo and S. K. Noh, “Green tea as inhibitor of the intestinal absorption of lipids: potential mechanism for its lipid-lowering effect,” Journal of Nutritional Biochemistry, vol. 18, no. 3, pp. 179–183, 2007. View at Publisher · View at Google Scholar · View at PubMed
  56. W. S. Kang, I. H. Lim, D. Y. Yuk et al., “Antithrombotic activities of green tea catechins and (-)-epigallocatechin gallate,” Thrombosis Research, vol. 96, no. 3, pp. 229–237, 1999. View at Publisher · View at Google Scholar
  57. P. T. Chan, W. P. Fong, Y. L. Cheung, Y. Huang, W. K. Ho, and Z. Y. Chen, “Jasmine green tea epicatechins are hypolipidemic in hamsters (Mesocricetus auratus) fed a high fat diet,” Journal of Nutrition, vol. 129, no. 6, pp. 1094–1101, 1999. View at Google Scholar
  58. A. Sachinidis, R. A. Skach, C. Seul et al., “Inhibition of the PDGF beta-receptor tyrosine phosphorylation and its downstream intracellular signal transduction pathway in rat and human vascular smooth muscle cells by different catechins,” The FASEB Journal, vol. 16, no. 8, pp. 893–895, 2002. View at Google Scholar
  59. L. Arab, W. Liu, and D. Elashoff, “Green and black tea consumption and risk of stroke: a meta-analysis,” Stroke, vol. 40, no. 5, pp. 1786–1792, 2009. View at Publisher · View at Google Scholar · View at PubMed
  60. N. Iwai, H. Ohshiro, Y. Kurozawa et al., “Relationship between coffee and green tea consumption and all-cause mortality in a cohort of a rural Japanese population,” Journal of Epidemiology, vol. 12, no. 3, pp. 191–198, 2002. View at Google Scholar
  61. S. Kuriyama, “The relation between green tea consumption and cardiovascular disease as evidenced by epidemiological studies,” Journal of Nutrition, vol. 138, no. 8, pp. 1548S–1553S, 2008. View at Google Scholar
  62. N. Alexopoulos, C. Vlachopoulos, K. Aznaouridis et al., “The acute effect of green tea consumption on endothelial function in healthy individuals,” European Journal of Cardiovascular Prevention and Rehabilitation, vol. 15, no. 3, pp. 300–305, 2008. View at Publisher · View at Google Scholar · View at PubMed
  63. C. Vlachopoulos, N. Alexopoulos, I. Dima, K. Aznaouridis, I. Andreadou, and C. Stefanadis, “Acute effect of black and green tea on aortic stiffness and wave reflections,” Journal of the American College of Nutrition, vol. 25, no. 3, pp. 216–223, 2006. View at Google Scholar
  64. J. M. Hodgson, I. B. Puddey, V. Burke, L. J. Beilin, and N. Jordan, “Effects on blood pressure of drinking green and black tea,” Journal of Hypertension, vol. 17, no. 4, pp. 457–463, 1999. View at Publisher · View at Google Scholar
  65. J. M. Hodgson, A. Devine, I. B. Puddey, S. Y. Chan, L. J. Beilin, and R. L. Prince, “Tea intake is inversely related to blood pressure in older women,” Journal of Nutrition, vol. 133, no. 9, pp. 2883–2886, 2003. View at Google Scholar
  66. K. Wakabayashi, S. Kono, K. Shinchi et al., “Habitual coffee consumption and blood pressure: a study of self-defense officials in Japan,” European Journal of Epidemiology, vol. 14, no. 7, pp. 669–673, 1998. View at Publisher · View at Google Scholar
  67. S. Tokunaga, I. R. White, C. Frost et al., “Green tea consumption and serum lipids and lipoproteins in a population of healthy workers in Japan,” Annals of Epidemiology, vol. 12, no. 3, pp. 157–165, 2002. View at Publisher · View at Google Scholar
  68. T. Matsuyama, Y. Tanaka, I. Kamimaki, T. Nagao, and I. Tokimitsu, “Catechin safely improved higher levels of fatness, blood pressure, and cholesterol in children,” Obesity, vol. 16, no. 6, pp. 1338–1348, 2008. View at Publisher · View at Google Scholar · View at PubMed
  69. M. P. Nantz, C. A. Rowe, J. F. Bukowski, and S. S. Percival, “Standardized capsule of Camellia sinensis lowers cardiovascular risk factors in a randomized, double-blind, placebo-controlled study,” Nutrition, vol. 25, no. 2, pp. 147–154, 2009. View at Publisher · View at Google Scholar · View at PubMed
  70. S. Inami, M. Takano, M. Yamamoto et al., “Tea catechin consumption reduces circulating oxidized low-density lipoprotein,” International Heart Journal, vol. 48, no. 6, pp. 725–732, 2007. View at Publisher · View at Google Scholar
  71. D. Erba, P. Riso, A. Bordoni, P. Foti, P. L. Biagi, and G. Testolin, “Effectiveness of moderate green tea consumption on antioxidative status and plasma lipid profile in humans,” Journal of Nutritional Biochemistry, vol. 16, no. 3, pp. 144–149, 2005. View at Publisher · View at Google Scholar · View at PubMed
  72. S. J. Duffy, J. F. Keaney Jr., M. Holbrook et al., “Short- and long-term black tea consumption reverses endothelial dysfunction in patients with coronary artery disease,” Circulation, vol. 104, no. 2, pp. 151–156, 2001. View at Google Scholar
  73. S. J. Duffy, J. A. Vita, M. Holbrook, P. L. Swerdloff, and J. F. Keaney Jr., “Effect of acute and chronic tea consumption on platelet aggregation in patients with coronary artery disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 21, no. 6, pp. 1084–1089, 2001. View at Google Scholar
  74. M. Lorenz, J. Urban, U. Engelhardt, G. Baumann, K. Stangl, and V. Stangl, “Green and black tea are equally potent stimuli of NO production and vasodilation: new insights into tea ingredients involved,” Basic Research in Cardiology, vol. 104, no. 1, pp. 100–110, 2009. View at Publisher · View at Google Scholar · View at PubMed
  75. S. M. Henning, C. Fajardo-Lira, H. W. Lee, A. A. Youssefian, V. L. W. Go, and D. Heber, “Catechin content of 18 teas and a green tea extract supplement correlates with the antioxidant capacity,” Nutrition and Cancer, vol. 45, no. 2, pp. 226–235, 2003. View at Google Scholar
  76. L. K. Leung, Y. Su, R. Chen, Z. Zhang, Y. Huang, and Z. Y. Chen, “Theaflavins in black tea and catechins in green tea are equally effective antioxidants,” Journal of Nutrition, vol. 131, no. 9, pp. 2248–2251, 2001. View at Google Scholar
  77. H. D. Sesso, R. S. Paffenbarger, Y. Oguma, and I. M. Lee, “Lack of association between tea and cardiovascular disease in college alumni,” International Journal of Epidemiology, vol. 32, no. 4, pp. 527–533, 2003. View at Publisher · View at Google Scholar
  78. Y. Mineharu, A. Koizumi, Y. Wada et al., “Coffee, green tea, black tea and oolong tea consumption and risk of mortality from cardiovascular disease in Japanese men and women,” Journal of Epidemiology and Community Health, vol. 65, no. 3, pp. 230–240, 2011. View at Publisher · View at Google Scholar · View at PubMed
  79. M. G. Hertog, E. J. Feskens, P. C. Hollman, M. B. Katan, and D. Kromhout, “Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly study,” Lancet, vol. 342, no. 8878, pp. 1007–1011, 1993. View at Publisher · View at Google Scholar
  80. J. Ferrières, “The French paradox: lessons for other countries,” Heart, vol. 90, no. 1, pp. 107–111, 2004. View at Google Scholar
  81. M. F. Ullah and M. W. Khan, “Food as medicine: potential therapeutic tendencies of plant derived polyphenolic compounds,” Asian Pacific Journal of Cancer Prevention, vol. 9, no. 2, pp. 187–195, 2008. View at Google Scholar
  82. A. L. Waterhouse, “Wine phenolics,” Annals of the New York Academy of Sciences, vol. 957, pp. 21–36, 2002. View at Google Scholar
  83. S. Maxwell, A. Cruickshank, and G. Thorpe, “Red wine and antioxidant activity in serum,” Lancet, vol. 344, no. 8916, pp. 193–194, 1994. View at Google Scholar
  84. A. Di Castelnuovo, S. Rotondo, L. Iacoviello, M. B. Donati, and G. De Gaetano, “Meta-analysis of wine and beer consumption in relation to vascular risk,” Circulation, vol. 105, no. 24, pp. 2836–2844, 2002. View at Publisher · View at Google Scholar · View at Scopus
  85. A. S. Hansen, P. Marckmann, L. O. Dragsted, I. L. Finné Nielsen, S. E. Nielsen, and M. Grønbæk, “Effect of red wine and red grape extract on blood lipids, haemostatic factors, and other risk factors for cardiovascular disease,” European Journal of Clinical Nutrition, vol. 59, no. 3, pp. 449–455, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  86. K. N. Karatzi, C. M. Papamichael, E. N. Karatzis et al., “Red wine acutely induces favorable effects on wave reflections and central pressures in coronary artery disease patients,” American Journal of Hypertension, vol. 18, no. 9, part 1, pp. 1161–1167, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  87. M. Hashimoto, S. Kim, M. Eto et al., “Effect of acute intake of red wine on flow-mediated vasodilatation of the brachial artery,” American Journal of Cardiology, vol. 88, no. 12, article A1459, pp. 1457–1460, 2001. View at Publisher · View at Google Scholar · View at Scopus
  88. S. Agewall, S. Wright, R. N. Doughty, G. A. Whalley, M. Duxbury, and N. Sharpe, “Does a glass of red wine improve endothelial function?” European Heart Journal, vol. 21, no. 1, pp. 74–78, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  89. A. van de Wiel and D. W. de Lange, “Cardiovascular risk is more related to drinking pattern than to the type of alcoholic drinks,” Netherlands Journal of Medicine, vol. 66, no. 11, pp. 467–473, 2008. View at Google Scholar · View at Scopus
  90. K. J. Mukamal, K. M. Conigrave, M. A. Mittleman et al., “Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men,” New England Journal of Medicine, vol. 348, no. 2, pp. 109–118, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  91. R. Hattori, H. Otani, N. Maulik, and D. K. Das, “Pharmacological preconditioning with resveratrol: role of nitric oxide,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 282, no. 6, pp. H1988–H1995, 2002. View at Google Scholar · View at Scopus
  92. L. Frémont, L. Belguendouz, and S. Delpal, “Antioxidant activity of resveratrol and alcohol-free wine polyphenols related to LDL oxidation and polyunsaturated fatty acids,” Life Sciences, vol. 64, no. 26, pp. 2511–2521, 1999. View at Publisher · View at Google Scholar · View at Scopus
  93. J. Zou, Y. Huang, Q. Chen, E. Wei, K. Cao, and J. M. Wu, “Effects of resveratrol on oxidative modification of human low density lipoprotein,” Chinese Medical Journal, vol. 113, no. 2, pp. 99–102, 2000. View at Google Scholar · View at Scopus
  94. S. E. Chow, Y. C. Hshu, J. S. Wang, and J. K. Chen, “Resveratrol attenuates oxLDL-stimulated NADPH oxidase activity and protects endothelial cells from oxidative functional damages,” Journal of Applied Physiology, vol. 102, no. 4, pp. 1520–1527, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  95. S. Das and D. K. Das, “Anti-inflammatory responses of resveratrol,” Inflammation and Allergy—Drug Targets, vol. 6, no. 3, pp. 168–173, 2007. View at Publisher · View at Google Scholar · View at Scopus
  96. Z. Ungvari, N. Labinskyy, P. Mukhopadhyay et al., “Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 297, no. 5, pp. H1876–H1881, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  97. L. M. Szewczuk, L. Forti, L. A. Stivala, and T. M. Penning, “Resveratrol is a peroxidase-mediated inactivator of COX-1 but not COX-2: a mechanistic approach to the design of COX-1 selective agents,” Journal of Biological Chemistry, vol. 279, no. 21, pp. 22727–22737, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  98. S. Shigematsu, S. Ishida, M. Hara et al., “Resveratrol, a red wine constituent polyphenol, prevents superoxide-dependent inflammatory responses induced by ischemia/reperfusion, platelet-activating factor, or oxidants,” Free Radical Biology and Medicine, vol. 34, no. 7, pp. 810–817, 2003. View at Publisher · View at Google Scholar · View at Scopus
  99. S. Das, V. K. Alagappan, D. Bagchi, H. S. Sharma, N. Maulik, and D. K. Das, “Coordinated induction of iNOS-VEGF-KDR-eNOS after resveratrol consumption: a potential mechanism for resveratrol preconditioning of the heart,” Vascular Pharmacology, vol. 42, no. 5-6, pp. 281–289, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  100. P. Gresele, P. Pignatelli, G. Guglielmini et al., “Resveratrol, at concentrations attainable with moderate wine consumption, stimulates human platelet nitric oxide production,” Journal of Nutrition, vol. 138, no. 9, pp. 1602–1608, 2008. View at Google Scholar · View at Scopus
  101. T. Walle, F. Hsieh, M. H. DeLegge, J. E. Oatis, and U. K. Walle, “High absorption but very low bioavailability of oral resveratrol in humans,” Drug Metabolism and Disposition, vol. 32, no. 12, pp. 1377–1382, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  102. D. Bagchi, M. Bagchi, S. J. Stohs et al., “Free radicals and grape seed proanthocyanidin extract: importance in human health and disease prevention,” Toxicology, vol. 148, no. 2-3, pp. 187–197, 2000. View at Publisher · View at Google Scholar · View at Scopus
  103. D. Bagchi, A. Garg, R. L. Krohn et al., “Protective effects of grape seed proanthocyanidins and selected antioxidants against TPA-induced hepatic and brain lipid peroxidation and DNA fragmentation, and peritoneal macrophage activation in mice,” General Pharmacology, vol. 30, no. 5, pp. 771–776, 1998. View at Publisher · View at Google Scholar
  104. W. G. Li, X. Y. Zhang, Y. J. Wu, and X. Tian, “Anti-inflammatory effect and mechanism of proanthocyanidins from grape seeds,” Acta Pharmacologica Sinica, vol. 22, no. 12, pp. 1117–1120, 2001. View at Google Scholar · View at Scopus
  105. F. Natella, F. Belelli, V. Gentili, F. Ursini, and C. Scaccini, “Grape seed proanthocyanidins prevent plasma postprandial oxidative stress in humans,” Journal of Agricultural and Food Chemistry, vol. 50, no. 26, pp. 7720–7725, 2002. View at Publisher · View at Google Scholar · View at Scopus
  106. S. Egert, A. Bosy-Westphal, J. Seiberl et al., “Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study,” British Journal of Nutrition, vol. 102, no. 7, pp. 1065–1074, 2009. View at Publisher · View at Google Scholar · View at PubMed
  107. E. B. Rimm, M. B. Katan, A. Ascherio, M. J. Stampfer, and W. C. Willett, “Relation between intake of flavonoids and risk for coronary heart disease in male health professionals,” Annals of Internal Medicine, vol. 125, no. 5, pp. 384–389, 1996. View at Google Scholar · View at Scopus
  108. J. Mursu, T. Nurmi, T. P. Tuomainen, A. Ruusunen, J. T. Salonen, and S. Voutilainen, “The intake of flavonoids and carotid atherosclerosis: the Kuopio Ischaemic Heart Disease Risk Factor Study,” British Journal of Nutrition, vol. 98, no. 4, pp. 814–818, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  109. N. P. Riksen, G. A. Rongen, and P. Smits, “Acute and long-term cardiovascular effects of coffee: implications for coronary heart disease,” Pharmacology and Therapeutics, vol. 121, no. 2, pp. 185–191, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  110. C. M. Papamichael, K. A. Aznaouridis, E. N. Karatzis et al., “Effect of coffee on endothelial function in healthy subjects: the role of caffeine,” Clinical Science, vol. 109, no. 1, pp. 55–60, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  111. M. C. Cornelis and A. El-Sohemy, “Coffee, caffeine, and coronary heart disease,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 10, no. 6, pp. 745–751, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  112. B. B. Fredholm, K. Bättig, J. Holmén, A. Nehlig, and E. E. Zvartau, “Actions of caffeine in the brain with special reference to factors that contribute to its widespread use,” Pharmacological Reviews, vol. 51, no. 1, pp. 83–133, 1999. View at Google Scholar · View at Scopus
  113. R. Urgert and M. B. Katan, “The cholesterol-raising factor from coffee beans,” Annual Review of Nutrition, vol. 17, pp. 305–324, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  114. P. Verhoef, W. J. Pasman, T. Van Vliet, R. Urgert, and M. B. Katan, “Contribution of caffeine to the homocysteine-raising effect of coffee: a randomized controlled trial in humans,” American Journal of Clinical Nutrition, vol. 76, no. 6, pp. 1244–1248, 2002. View at Google Scholar · View at Scopus
  115. M. A. Pereira, E. D. Parker, and A. R. Folsom, “Coffee consumption and risk of type 2 diabetes mellitus: an 11-year prospective study of 28 812 postmenopausal women,” Archives of Internal Medicine, vol. 166, no. 12, pp. 1311–1316, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  116. A. O. Odegaard, M. A. Pereira, W. P. Koh, K. Arakawa, H. P. Lee, and M. C. Yu, “Coffee, tea, and incident type 2 diabetes: the Singapore Chinese Health study,” American Journal of Clinical Nutrition, vol. 88, no. 4, pp. 979–985, 2008. View at Google Scholar · View at Scopus
  117. M. C. Cornelis, A. El-Sohemy, E. K. Kabagambe, and H. Campos, “Coffee, CYP1A2 genotype, and risk of myocardial infarction,” Journal of the American Medical Association, vol. 295, no. 10, pp. 1135–1141, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  118. E. Lopez-Garcia, R. M. van Dam, T. Y. Li, F. Rodriguez-Artalejo, and F. B. Hu, “The relationship of coffee consumption with mortality,” Annals of Internal Medicine, vol. 148, no. 12, pp. 904–914, 2008. View at Google Scholar · View at Scopus
  119. F. Valagussa, M. G. Franzosi, E. Geraci et al., “Dietary supplementation with N-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial,” Lancet, vol. 354, no. 9177, pp. 447–455, 1999. View at Publisher · View at Google Scholar
  120. R. Marchioli, F. Barzi, E. Bomba et al., “Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione,” Circulation, vol. 105, no. 16, pp. 1897–1903, 2002. View at Publisher · View at Google Scholar
  121. M. Svensson, E. B. Schmidt, K. A. Jørgensen, and J. H. Christensen, “N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial,” Clinical Journal of the American Society of Nephrology, vol. 1, no. 4, pp. 780–786, 2006. View at Publisher · View at Google Scholar · View at PubMed
  122. L. Tavazzi, A. P. Maggioni, R. Marchioli et al., “Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial,” Lancet, vol. 372, no. 9645, pp. 1223–1230, 2008. View at Google Scholar
  123. M. Yokoyama, H. Origasa, M. Matsuzaki et al., “Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis,” Lancet, vol. 369, no. 9567, pp. 1090–1098, 2007. View at Publisher · View at Google Scholar · View at PubMed
  124. H. O. Bang, J. Dyerberg, and A. B. Nielsen, “Plasma lipid and lipoprotein pattern in Greenlandic West-coast Eskimos,” Lancet, vol. 1, no. 7710, pp. 1143–1145, 1971. View at Google Scholar
  125. J. L. Breslow, “n-3 Fatty acids and cardiovascular disease,” American Journal of Clinical Nutrition, vol. 83, no. 6, pp. 1477S–1482S, 2006. View at Google Scholar
  126. L. Hooper, R. L. Thompson, R. A. Harrison et al., “Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review,” British Medical Journal, vol. 332, no. 7544, pp. 752–760, 2006. View at Publisher · View at Google Scholar · View at PubMed
  127. K. He, “Fish, long-chain omega-3 polyunsaturated fatty acids and prevention ofcardiovascular disease—eat fish or take fish oil supplement?” Progress in Cardiovascular Diseases, vol. 52, no. 2, pp. 95–114, 2009. View at Publisher · View at Google Scholar · View at PubMed
  128. F. Thies, J. M. Garry, P. Yaqoob et al., “Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomised controlled trial,” Lancet, vol. 361, no. 9356, pp. 477–485, 2003. View at Publisher · View at Google Scholar · View at PubMed
  129. C. Wang, W. S. Harris, M. Chung et al., “n-3 Fatty acids from fish or fish-oil supplements, but not α-linolenic acid, benefit cardiovascular disease outcomes in primary- and secondary-prevention studies: a systematic review,” American Journal of Clinical Nutrition, vol. 84, no. 1, pp. 5–17, 2006. View at Google Scholar
  130. M. C. Morris, F. Sacks, and B. Rosner, “Does fish oil lower blood pressure? A meta-analysis of controlled trials,” Circulation, vol. 88, no. 2, pp. 523–533, 1993. View at Google Scholar
  131. G. D. Eslick, P. R. Howe, C. Smith, R. Priest, and A. Bensoussan, “Benefits of fish oil supplementation in hyperlipidemia: a systematic review and meta-analysis,” International Journal of Cardiology, vol. 136, no. 1, pp. 4–16, 2009. View at Publisher · View at Google Scholar · View at PubMed
  132. M. L. Burr, A. M. Fehily, J. F. Gilbert et al., “Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART),” Lancet, vol. 2, no. 8666, pp. 757–761, 1989. View at Google Scholar
  133. C. M. Albert, C. H. Hennekens, C. J. O'Donnell et al., “Fish consumption and risk of sudden cardiac death,” Journal of the American Medical Association, vol. 279, no. 1, pp. 23–28, 1998. View at Publisher · View at Google Scholar · View at Scopus
  134. C. M. Albert, H. Campos, M. J. Stampfer et al., “Blood levels of long-chain n-3 fatty acids and the risk of sudden death,” New England Journal of Medicine, vol. 346, no. 15, pp. 1113–1118, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  135. H. M. Den Ruijter, G. Berecki, T. Opthof, A. O. Verkerk, P. L. Zock, and R. Coronel, “Pro- and antiarrhythmic properties of a diet rich in fish oil,” Cardiovascular Research, vol. 73, no. 2, pp. 316–325, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  136. H. León, M. C. Shibata, S. Sivakumaran, M. Dorgan, T. Chatterley, and R. T. Tsuyuki, “Effect of fish oil on arrhythmias and mortality: systematic review,” British Medical Journal, vol. 337, p. a2931, 2008. View at Google Scholar
  137. L. J. Bjerregaard, A. M. Joensen, C. Dethlefsen et al., “Fish intake and acute coronary syndrome,” European Heart Journal, vol. 31, no. 1, pp. 29–34, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  138. T. A. Pearson, S. N. Blair, S. R. Daniels et al., “AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. American heart association science advisory and coordinating committee,” Circulation, vol. 106, no. 3, pp. 388–391, 2002. View at Google Scholar
  139. S. C. Smith Jr., J. Allen, S. N. Blair et al., “AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update—endorsed by the National Heart, Lung, and Blood Institute,” Circulation, vol. 113, no. 19, pp. 2363–2372, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  140. K. Rahman and G. M. Lowe, “Garlic and cardiovascular disease: a critical review,” Journal of Nutrition, vol. 136, no. 3, pp. 736S–740S, 2006. View at Google Scholar
  141. N. H. Mashour, G. I. Lin, and W. H. Frishman, “Herbal medicine for the treatment of cardiovascular disease: clinical considerations,” Archives of Internal Medicine, vol. 158, no. 20, pp. 2225–2234, 1998. View at Publisher · View at Google Scholar · View at Scopus
  142. J. Kleijnen, P. Knipschild, and G. ter Riet, “Garlic, onions and cardiovascular risk factors. A review of the evidence from human experiments with emphasis on commercially available preparations,” British Journal of Clinical Pharmacology, vol. 28, no. 5, pp. 535–544, 1989. View at Google Scholar · View at Scopus
  143. M. Steiner, A. H. Khan, D. Holbert, and R. I. Lin, “A double-blind crossover study in moderately hypercholesterolemic men that compared the effect of aged garlic extract and placebo administration on blood lipids,” American Journal of Clinical Nutrition, vol. 64, no. 6, pp. 866–870, 1996. View at Google Scholar · View at Scopus
  144. J. L. Isaacsohn, M. Moser, E. A. Stein et al., “Garlic powder and plasma lipids and lipoproteins: a multicenter, randomized, placebo-controlled trial,” Archives of Internal Medicine, vol. 158, no. 11, pp. 1189–1194, 1998. View at Publisher · View at Google Scholar · View at Scopus
  145. A. K. Jain, R. Vargas, S. Gotzkowsky, and F. G. McMahon, “Can garlic reduce levels of serum lipids? A controlled clinical study,” American Journal of Medicine, vol. 94, no. 6, pp. 632–635, 1993. View at Publisher · View at Google Scholar · View at Scopus
  146. B. S. Kendler, “Garlic (Allium sativum) and onion (Allium cepa): a review of their relationship to cardiovascular disease,” Preventive Medicine, vol. 16, no. 5, pp. 670–685, 1987. View at Google Scholar · View at Scopus
  147. H. A. Neil, C. A. Silagy, T. Lancaster et al., “Garlic powder in the treatment of moderate hyperlipidaemia: a controlled trial and meta-analysis,” Journal of the Royal College of Physicians of London, vol. 30, no. 4, pp. 329–334, 1996. View at Google Scholar · View at Scopus
  148. C. Silagy and A. Neil, “Garlic as a lipid lowering agent—a meta-analysis,” Journal of the Royal College of Physicians of London, vol. 28, no. 1, pp. 39–45, 1994. View at Google Scholar · View at Scopus
  149. C. A. Silagy and H. A. Neil, “A meta-analysis of the effect of garlic on blood pressure,” Journal of Hypertension, vol. 12, no. 4, pp. 463–468, 1994. View at Google Scholar · View at Scopus
  150. K. M. Reinhart, R. Talati, C. M. White, and C. I. Coleman, “The impact of garlic on lipid parameters: a systematic review and meta-analysis,” Nutrition Research Reviews, vol. 22, no. 1, pp. 39–48, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  151. S. Simons, H. Wollersheim, and T. Thien, “A systematic review on the influence of trial quality on the effect of garlic on blood pressure,” Netherlands Journal of Medicine, vol. 67, no. 6, pp. 212–219, 2009. View at Google Scholar · View at Scopus
  152. A. Bordia, S. K. Verma, and K. C. Srivastava, “Effect of garlic on platelet aggregation in humans: a study in healthy subjects and patients with coronary artery disease,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 55, no. 3, pp. 201–205, 1996. View at Publisher · View at Google Scholar
  153. M. Ali and M. Thomson, “Consumption of a garlic clove a day could be beneficial in preventing thrombosis,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 53, no. 3, pp. 211–212, 1995. View at Publisher · View at Google Scholar · View at Scopus
  154. K. Breithaupt-Grögler, M. Ling, H. Boudoulas, and G. G. Belz, “Protective effect of chronic garlic intake on elastic properties of aorta in the elderly,” Circulation, vol. 96, no. 8, pp. 2649–2655, 1997. View at Google Scholar · View at Scopus
  155. T. A. Delaney and A. M. Donnelly, “Garlic dermatitis,” Australasian Journal of Dermatology, vol. 37, no. 2, pp. 109–110, 1996. View at Google Scholar · View at Scopus
  156. K. D. Rose, P. D. Croissant, C. F. Parliament, and M. B. Levin, “Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: a case report,” Neurosurgery, vol. 26, no. 5, pp. 880–882, 1990. View at Google Scholar · View at Scopus
  157. E. J. Wang, M. Barecki-Roach, and W. W. Johnson, “Elevation of P-glycoprotein function by a catechin in green tea,” Biochemical and Biophysical Research Communications, vol. 297, no. 2, pp. 412–418, 2002. View at Publisher · View at Google Scholar · View at Scopus
  158. Y. Wang, J. Cao, and S. Zeng, “Involvement of P-glycoprotein in regulating cellular levels of Ginkgo flavonols: quercetin, kaempferol, and isorhamnetin,” Journal of Pharmacy and Pharmacology, vol. 57, no. 6, pp. 751–758, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  159. New Zealand Guidelines Group, New Zealand Cardiovascular Guidelines Handbook, 2005.